Have a personal or library account? Click to login
Do we use methylation of NFATC1 and FOS genes as a biomarker for postmenopausal osteoporosis? Cover

Do we use methylation of NFATC1 and FOS genes as a biomarker for postmenopausal osteoporosis?

Balkan Journal of Medical Genetics
Volume 23 (2020): Issue 2 (November 2020)
By: R Kalkan and  O Tosun  
Open Access
|Mar 2021

Figures & Tables

Figure 1

Methylated NFATC1 patients. The NFATC1 unmethylated control was orange, the methylated control was red. Patients 41 and 34 were methylated.
Methylated NFATC1 patients. The NFATC1 unmethylated control was orange, the methylated control was red. Patients 41 and 34 were methylated.

Figure 2

Methylated FOS patients. The FOS unmethylated control was purple, the methylated control was red. Patients 8 and 19 were methylated.
Methylated FOS patients. The FOS unmethylated control was purple, the methylated control was red. Patients 8 and 19 were methylated.

Methylation status of NFATC1 and FOS in post- and premenopausal women_

ParametersPostmenopausal n (%)Premenopausal n (%)p Value
NFATC1 methylated11 (31.4)19 (63.3)0.010
NFATC1 unmethylated24 (68.8)11 (36.7)
FOS methylated6 (17.1)5 (16.7)>0.050
FOS unmethylated29 (82.9)25 (83.3)
DOI: https://doi.org/10.2478/bjmg-2020-0021 | Journal eISSN: 2199-5761
Journal RSS Feed
Language: English
Page range: 35 - 40
Published on: Mar 23, 2021
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Methylation sensitive-high resolution melting (MS-HRM),
Methylation,
Postmenopause,
Premenopause
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2021 R Kalkan, O Tosun, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 23 (2020): Issue 2 (November 2020)Next article